A 3-dimensional, multi-layered approach combining modalities targeting different manifestations is recommended for achieving optimal esthetic outcomes. To date, studies reporting same-day treatment with dermal fillers and botulinum toxin have not been published. This article documents the practical use of a single-visit, pan-facial multimodal approach in addressing the varying esthetic needs of 8 Asian adults. The case series included male or female patients of varying age and degrees of facial fat, who received combination treatment with calcium hydroxylapatite filler, polydensified hyaluronic acid filler, and incobotulinumtoxin A in a single visit in August 2016 at a treatment center in Taiwan. Treatments were individualized based on the needs of each patient, according to guideline recommendations. The agents, with distinctive rheological properties indicated for different purposes, were applied sequentially across different facial tissue planes within a single visit. Patients were monitored for development of side effects after treatment. Photographs taken before treatment and 2 weeks after treatment were evaluated by the treating physicians. For all patients, treatment produced substantial improvements in all treated facial areas. Inherent morphological deficiencies in younger patients were addressed, age-related changes in older patients were corrected, and facial sexual dimorphism was enhanced in male and female patients. No major side effects occurred after treatment. This case series showcases the real-life implementation of a flexible, single-visit, multimodal approach that can be adapted for a variety of indications.
From the CHAO Institute of Aesthetic Medicine, Taipei, Taiwan.
Published online 2 October 2018.
Received for publication March 14, 2018; accepted April 23, 2018.
Some of the results of this case series were presented at the Taiwan Dermatology Aesthetic Conference (TDAC) 2017 in Taiwan and International Master Course on Aging Science (IMCAS) Asia 2017, Indonesia.
Disclosure: Merz Pharmaceuticals GmbH provided the following medications used in this study: Radiesse®, Belotero Intense®, Belotero Balance®, and Xeomin®/Bocouture®. Dr. Chao received a study grant from Merz Asia Pacific Pte Ltd to conduct this case series. He is a scientific advisory board member, consultant, speaker, and trainer for Merz Asia Pacific Pte Ltd. The Article Processing Charge was paid for by Merz Asia Pacific Pte Ltd.
Yates Y. Y. Chao, MD, CHAO Institute of Aesthetic Medicine, 3/F 8 Chin Chen St, 105 Taipei City, Taiwan, E-mail: firstname.lastname@example.org
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.